NCT05018585: An ongoing trial by Diamyd Medical AB
This trial is ongoing. It must report results 3Â years from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05018585 |
|---|---|
| Title | A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Diamyd® to Preserve Endogenous Beta Cell Function in Adolescents and Adults With Recently Diagnosed Type 1 Diabetes, Carrying the Genetic HLA DR3-DQ2 Haplotype |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 19, 2022 |
| Completion date | Dec. 31, 2027 |
| Required reporting date | Dec. 30, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |